Zhao W H, Hu Z Q, Okubo S, Hara Y, Shimamura T
Department of Microbiology and Immunology, Showa University School of Medicine, Tokyo, Japan.
Antimicrob Agents Chemother. 2001 Jun;45(6):1737-42. doi: 10.1128/AAC.45.6.1737-1742.2001.
Compared to MICs (more than 800 microg/ml) of (-)-epigallocatechin gallate (EGCg) against Escherchia coli, MICs of EGCg against methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MSSA and MRSA) were 100 microg/ml or less. Furthermore, less than 25 microg EGCg per ml obviously reversed the high level resistance of MRSA to all types of tested beta-lactams, including benzylpenicillin, oxacillin, methicillin, ampicillin, and cephalexin. EGCg also induced a supersusceptibility to beta-lactams in MSSA which does not express mecA, encoding penicillin-binding protein 2' (PBP2'). The fractional inhibitory concentration (FIC) indices of the tested beta-lactams against 25 isolates of MRSA were from 0.126 to 0.625 in combination with 6.25, 12.5 or 25 microg of EGCg per ml. However, no synergism was observed between EGCg and ampicillin against E. coli. EGCg largely reduced the tolerance of MRSA and MSSA to high ionic strength and low osmotic pressure in their external atmosphere, indicating damage of the cell wall. Unlike dextran and lipopolysaccharide, peptidoglycan from S. aureus blocked both the antibacterial activity of EGCg and the synergism between EGCg and oxacillin, suggesting a direct binding of EGCg with peptidoglycan on the cell wall. EGCg showed a synergistic effect with DL-cycloserine (an inhibitor of cell wall synthesis unrelated to PBP2') but additive or indifferent effect with inhibitors of protein and nuclear acid synthesis. EGCg did not suppress either PBP2' mRNA expression or PBP2' production, as confirmed by reverse transcription-PCR and a semiquantitative PBP2' latex agglutination assay, indicating an irrelevance between the synergy and PBP2' production. In summary, both EGCg and beta-lactams directly or indirectly attack the same site, peptidoglycan on the cell wall. EGCg synergizes the activity of beta-lactams against MRSA owing to interference with the integrity of the cell wall through direct binding to peptidoglycan.
与(-)-表没食子儿茶素没食子酸酯(EGCg)对大肠杆菌的最低抑菌浓度(超过800微克/毫升)相比,EGCg对甲氧西林敏感和耐甲氧西林金黄色葡萄球菌(MSSA和MRSA)的最低抑菌浓度为100微克/毫升或更低。此外,每毫升低于25微克的EGCg明显逆转了MRSA对所有测试的β-内酰胺类药物的高水平耐药性,包括苄青霉素、苯唑西林、甲氧西林、氨苄青霉素和头孢氨苄。EGCg还使不表达编码青霉素结合蛋白2'(PBP2')的mecA的MSSA对β-内酰胺类药物产生超敏感性。测试的β-内酰胺类药物与每毫升6.25、12.5或25微克的EGCg联合使用时,对25株MRSA的部分抑菌浓度(FIC)指数为0.126至0.625。然而,未观察到EGCg与氨苄青霉素对大肠杆菌有协同作用。EGCg在很大程度上降低了MRSA和MSSA对其外部环境中高离子强度和低渗透压的耐受性,表明细胞壁受到损伤。与右旋糖酐和脂多糖不同,金黄色葡萄球菌的肽聚糖既阻断了EGCg的抗菌活性,也阻断了EGCg与苯唑西林之间的协同作用,这表明EGCg与细胞壁上的肽聚糖直接结合。EGCg与DL-环丝氨酸(一种与PBP2'无关的细胞壁合成抑制剂)显示出协同作用,但与蛋白质和核酸合成抑制剂具有相加或无作用的效果。通过逆转录聚合酶链反应和半定量PBP2'乳胶凝集试验证实,EGCg既不抑制PBP2' mRNA表达,也不抑制PBP2'的产生,这表明协同作用与PBP2'的产生无关。总之,EGCg和β-内酰胺类药物都直接或间接攻击同一个位点,即细胞壁上的肽聚糖。由于EGCg通过直接与肽聚糖结合干扰细胞壁的完整性,从而增强了β-内酰胺类药物对MRSA的活性。